CJC-1295 with DAC vs without DAC

Evidence summary: CJC-1295 with Drug Affinity Complex is a long-acting GHRH analog designed for covalent albumin binding. The material commonly sold as CJC-1295 without DAC is modified GRF(1-29), a distinct tetrasubstituted peptide. Human multi-day pharmacokinetic findings belong to the DAC molecule and should not be transferred to the no-DAC product.

Key findings

  • DAC changes molecular identity and produces prolonged albumin-linked exposure.
  • The 2006 human trials studied CJC-1295 with DAC, not modified GRF(1-29).
  • No published pharmacokinetic study of the exact commercial no-DAC molecule was identified.

Two names that should not be collapsed

CJC-1295 with DAC incorporates a reactive group that forms a covalent bond with albumin. Modified GRF(1-29) lacks that DAC group. They therefore differ in structure, molecular mass and expected exposure.

A product record, label or COA should identify the exact molecule rather than treating 'CJC-1295' as sufficient.

Evidence for the DAC molecule

Jetté and colleagues described the albumin-binding design in preclinical work. Teichman and colleagues then studied CJC-1295 with DAC in healthy adults and estimated a 5.8–8.1 day half-life with multi-day GH and IGF-I effects.

Those short, industry-sponsored studies measured pharmacokinetics and endocrine biomarkers. They did not establish long-term outcomes or validate no-DAC material.

Evidence gap for modified GRF(1-29)

No published human or animal pharmacokinetic study of the exact tetrasubstituted no-DAC molecule was identified. Frequently repeated half-life figures are therefore not treated here as measured evidence.

Data for native GRF(1-29), sermorelin or CJC-1295-DAC provide context, not interchangeable proof.

Ipamorelin combinations remain untested

Ipamorelin activates a different receptor pathway, which creates a mechanistic combination hypothesis. No published human study was identified that co-administered ipamorelin with either CJC form.

A blended vial ratio is a product specification, not a clinically optimized or validated regimen.

Continue to the full evidence guide

Review the CJC-1295 and ipamorelin evidence brief

Frequently asked questions

Is CJC-1295 without DAC the same molecule?

No. The no-DAC product commonly refers to modified GRF(1-29), which lacks CJC-1295's albumin-binding DAC group.

Can the DAC half-life be used for no-DAC material?

No. The multi-day human estimate belongs to CJC-1295 with DAC.

Is CJC-1295 plus ipamorelin proven synergistic?

No published human co-administration study was identified.

Primary references

  1. Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PubMed 15817669
  2. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PubMed 17018654
  4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822

Related research materials

Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.